BriaCell Therapeutics Corp.
Suite 300 – 235 West 15th Street
West Vancouver, BC V7T 2X1
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Division of Corporation Finance
Attention: Irene Paik, Joseph McCann, Franklin Wyman and Lisa Vanjoske
May 15, 2020 |
Re: | BriaCell Therapeutics Corp. |
Amendment No. 7 to Registration Statement on Form F-1 Filed May 18, 2020 | |
File No. 333-234292 |
Ladies and Gentlemen:
BriaCell Therapeutics Corp. (the “Company”) is hereby filing Amendment No. 7 to its Registration Statement on Form F-1/ Amendment No. 7 has been revised to reflect i) recent developments, ii) the Company’s financials for the fiscal quarter ended January 31, 2020 and iii) the assumed public offering price per Common Unit and Pre-funded Unit of $6.33 (the “Offering Price”). The Offering Price was not determined by any particular formula but rather through negotiations between the Company and the underwriter.
We hope the foregoing answers are responsive to your comments. Please do not hesitate to contact our counsel at (212) 930-9700 with any questions or comments regarding this correspondence.
Sincerely, | |
/s/ William V. Williams | |
William V. Williams |
cc: (via email)
Jamieson Bondarenko
Gadi Levin
Gregory Sichenzia, Esq.
Avital Perlman, Esq.
Aaron Sonshine
Virgil Z. Hlus